Long plagued by suits over its metal-on-metal hip implants, Johnson & Johnson is weighing a $250 million settlement to resolve more claims that were not covered under an earlier accord.
Johnson & Johnson scored a victory in the first case to go to trial for its metal-on-metal hip implants, as a Texas jury ruled against a woman who claimed that Pinnacle devices made by the company's DePuy subsidiary poisoned her and caused undue pain and suffering.
Johnson & Johnson squared off with aggrieved metal-on-metal hip customer Kathleen Herlihy-Paoli in a case that the plaintiffs says could lead to a $5 billion-plus payout. Herlihy-Paoli's claims that the hips leaked metal into her bloodstream, leading to an infection that required the artificial hip to be removed.
Long beleaguered by claims related to defective all-metal hip implants, Johnson & Johnson is shoring up for its latest courtroom battle as the company faces the first trial for one of its artificial hip devices.
Johnson & Johnson's DePuy arm is recalling multiple lots of an orthopedic implant part prone to fracturing in some cases, and the FDA slapped its most-serious Class I status onto the effort. Limb loss is listed as one of the risks.
With more than 10,000 lawsuits already in the mix, Johnson & Johnson must deal with yet another patient's allegation's that company knowingly sold faulty metal hip implants and didn't warn the public.
Stryker's bottom line is already taking a hit from the escalating cost of its all-metal hip recalls. But lawsuits against the device maker are also rising, threatening to grab an even bigger chunk of the company's cash.
Johnson & Johnson has had enough with metal-on-metal and ceramic-on-metal hips, disclosing that it will leave those business lines entirely behind by the end of 2014.
After losing two jury trials, Johnson & Johnson/DePuy can now celebrate the fact that a jury has ruled in its favor regarding the company's ASR all metal hip implant.
Biomet posted a 9% sales hike last quarter thanks largely to its $280 million acquisition of DePuy's trauma business, but a ramp-up in costs and a hefty impairment charge rocketed its net loss up about 184%.